Jasper Therapeutics, Inc. (NASDAQ:JSPR – Free Report) – Stock analysts at Cantor Fitzgerald lowered their FY2024 EPS estimates for shares of Jasper Therapeutics in a report issued on Monday, November 13th. Cantor Fitzgerald analyst P. Stavropoulos now forecasts that the company will earn ($0.46) per share for the year, down from their previous estimate of ($0.43). Cantor Fitzgerald currently has a “Overweight” rating and a $6.00 price target on the stock. The consensus estimate for Jasper Therapeutics’ current full-year earnings is ($0.61) per share.
Other equities research analysts also recently issued reports about the company. Credit Suisse Group reaffirmed an “outperform” rating and set a $4.00 price target on shares of Jasper Therapeutics in a research note on Monday, August 14th. Capital One Financial initiated coverage on Jasper Therapeutics in a research note on Friday, August 11th. They set an “overweight” rating and a $7.00 price target for the company. Finally, William Blair reaffirmed an “outperform” rating on shares of Jasper Therapeutics in a research note on Wednesday, November 8th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $5.96.
Jasper Therapeutics Price Performance
NASDAQ JSPR opened at $0.61 on Thursday. The company has a 50 day simple moving average of $0.75 and a 200-day simple moving average of $1.20. The firm has a market capitalization of $67.81 million, a price-to-earnings ratio of -0.74 and a beta of 2.03. Jasper Therapeutics has a 52-week low of $0.39 and a 52-week high of $3.80.
Institutional Inflows and Outflows
Institutional investors have recently bought and sold shares of the company. Renaissance Technologies LLC raised its holdings in Jasper Therapeutics by 128.7% in the 4th quarter. Renaissance Technologies LLC now owns 65,400 shares of the company’s stock worth $32,000 after acquiring an additional 36,800 shares during the period. Gries Financial LLC acquired a new stake in Jasper Therapeutics in the 2nd quarter worth $33,000. Summit Trail Advisors LLC acquired a new position in shares of Jasper Therapeutics during the third quarter valued at about $46,000. Jump Financial LLC acquired a new position in shares of Jasper Therapeutics during the first quarter valued at about $60,000. Finally, State Street Corp lifted its stake in shares of Jasper Therapeutics by 51.2% in the second quarter. State Street Corp now owns 32,884 shares of the company’s stock valued at $63,000 after buying an additional 11,132 shares during the period. Institutional investors own 79.85% of the company’s stock.
About Jasper Therapeutics
Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and novel conditioning regimens for stem cell transplantation and ex-vivo gene therapy, a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation.
- Five stocks we like better than Jasper Therapeutics
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Amazon, Target, Walmart in a race for fastest delivery
- How to Invest in Canada for Beginners
- Palo Alto Networks: the one security stock to rule them all
- Profitably Trade Stocks at 52-Week Highs
- Is it time to buy the dip in Walmart shares?
Receive News & Ratings for Jasper Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jasper Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.